Compare CDNA & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | EVO |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 934.1M |
| IPO Year | 2007 | N/A |
| Metric | CDNA | EVO |
|---|---|---|
| Price | $21.60 | $3.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $28.00 | $7.00 |
| AVG Volume (30 Days) | ★ 652.5K | 85.0K |
| Earning Date | 04-28-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $48,324,000.00 | N/A |
| Revenue This Year | $16.01 | $1.37 |
| Revenue Next Year | $11.31 | $10.05 |
| P/E Ratio | $429.80 | ★ N/A |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $10.96 | $2.31 |
| 52 Week High | $23.24 | $4.48 |
| Indicator | CDNA | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 53.04 |
| Support Level | $15.80 | $2.88 |
| Resistance Level | $22.89 | $3.36 |
| Average True Range (ATR) | 1.00 | 0.09 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 76.54 | 54.34 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.